Silencing ITGA11 and Activating PI3K/AKT

siRNA against ITGA11 (Si-ITGA11#1, Si-ITGA11#2, Si-ITGA11 #3) and the corresponding negative control (Si-NC) were afforded by Geneharma (Shanghai, China). The PI3K/AKT agonist IGF-1 was obtained from MedChemExpress (Cat.No. HY-P70788, Shanghai, China) and adopted for activating the PI3K/AKT pathway at a dose of 50 ng/mL [15 (link)]. MKN45 and AGS cells were seeded on 24-well plates (2 × 10⁴ cells/well), kept at 37°C with 5% CO₂ for 24 hours, and transfected with si-ITGA11 or si-NC along with Lipofectamine® 3000 (Invitrogen; ThermoFisherScientific, Inc.). Following 24 hours, the culture medium was discarded and refreshed with a complete one. After another 24-hour culture, the transfection validity was measured by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blot (WB) [16 (link)].